P. 1
Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018

Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018

Views: 6|Likes:
Published by rob25ste
Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, 'Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006'2010. During 2010'2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market.ScopeThe report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)-Based Vacc
Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, 'Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006'2010. During 2010'2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market.ScopeThe report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)-Based Vacc

More info:

Categories:Types, Business/Law
Published by: rob25ste on Nov 11, 2011
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

10/10/2013

pdf

text

original

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, 'Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006'2010. During 2010'2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is

1

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market. Scope The report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine, heated-killed yeast-based vaccine etc. - Analysis of the current and future competition in the seven key countries cancer vaccines market. Key market players covered are Merck, NovaRx Corporation, NewLink Genetics Corporation, Bavarian Nordic, immatics biotechnologies GmbH, Oxford BioMedica, Biovex, Vaccinogen, Biovest International, Vaccinogen and GlaxoSmithKline. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the cancer vaccines market. - Analysis of key recent licensing and partnership agreements in cancer vaccines market.

2

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global cancer vaccines market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global cancer vaccines market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global cancer vaccines market landscape' ' Identify, understand and capitalize.

Table of Contents
1 Table of contents 1 Table of contents 4 1.1 List of Tables 6 1.2 List of Figures 7 2 Cancer Vaccines - Introduction 8 2.1 Overview 8 2.2 Epidemiology of Various Cancers 8 2.2.1 Cancer Incidence and Mortality in the US 8 2.2.2 Cancer Incidence and Mortality in Europe (EU5) 9

3

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

2.2.3 Cancer Incidence and Mortality in Japan. 9 2.3 Cancer Vaccines 10 2.3.1 Overview 10 2.4 Prophylactic Cancer Vaccines 14 2.4.1 Gardasil (Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant) 14 2.4.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant) 14 2.4.3 Cervical Cancer: An Introduction 15 2.5 Therapeutic Cancer Vaccines 16 2.5.1 Provenge 17 2.5.2 Prostate Cancer: An Introduction 17 2.5.3 Metastatic Prostate Cancer 18 2.6 Future of Cancer Vaccines 18 2.6.1 Drawbacks of Available Cancer Therapies 19 2.6.2 Benefits of the Upcoming Cancer Vaccines 19 2.7 GlobalData Pipeline Report Guidance 20 3 Cancer Vaccines - Market Characterization 21 3.1 Cancer Vaccines Market Size (2006-2010) ' Global 21 3.2 Cancer Vaccines Market Forecast (2010-2018) ' Global 22 3.3 Cancer Vaccines Market Size (2006-2010) ' The US 25 3.4 Cancer Vaccines Market Forecast (2010-2018) ' The US 26 3.5 Cancer Vaccines Market Size (2006-2010) ' France 28 3.6 Cancer Vaccines Market Forecast (2010-2018) ' France 29 3.7 Cancer Vaccines Market Size (2006-2010) ' Germany 31 3.8 Cancer Vaccines Market Forecast (2010-2018) ' Germany 32 3.9 Cancer Vaccines Market Size (2006-2010) ' Italy 34 3.10 Cancer Vaccines Market Forecast (2010-2018) ' Italy 35 3.11 Cancer Vaccines Market Size (2006-2010) ' Spain 37 3.12 Cancer Vaccines Market Forecast (2010-2018) ' Spain 38 3.13 Cancer Vaccines Market Size (2006-2010) ' The UK 40 3.14 Cancer Vaccines Market Forecast (2010-2018) ' The UK 41

4

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

3.15 Cancer Vaccines Market Size (2006-2010) ' Japan 43 3.16 Cancer Vaccines Market Forecast (2010-2018) ' Japan 43 3.17 Drivers and Barriers for the Cancer Vaccines Market 45 3.17.1 Drivers for the Cancer Vaccines Market 45 3.17.2 Barriers for the Cancer Vaccines Market 46 3.18 Opportunity and Unmet Need Analysis 47 3.19 Key Takeaway 48 4 Cancer Vaccines - Competitive Assessment 49 4.1 Overview 49 4.1.1 Strategic Competitor Assessment 49 4.2 Product Profiles for the Major Marketed Products in the Cancer Vaccines Therapeutics Market 50 4.2.1 Gardasil (HPV Quadrivalent (Type 6, 11, 16 and 18) Vaccine, Recombinant) 50 4.2.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant) 52 4.2.3 Provenge (sipuleucel-T) 54 4.3 Key Takeaway 55 5 Cancer Vaccines - Pipeline Assessment 56 5.1 Overview 56 5.2 Strategic Pipeline Assessment 56 5.3 Cancer Vaccines Pipeline ' Pipeline by Phases of Development 57 5.3.1 Prophylactic Cancer Vaccines ' Phase III Pipeline 57 5.3.2 Prophylactic Cancer Vaccines ' Phase II Pipeline 58 5.3.3 Prophylactic Cancer Vaccines ' Phase I/II Pipeline 58 5.3.4 Prophylactic Cancer Vaccines ' Phase I Pipeline 58 5.3.5 Prophylactic Cancer Vaccines ' Preclinical Pipeline 58 5.3.6 Therapeutics Cancer Vaccines' Phase III Pipeline 59 5.3.7 Therapeutics Cancer Vaccines ' Phase II Pipeline 60 5.3.8 Therapeutics Cancer Vaccines ' PhaseI/II Pipeline 66 5.3.9 Therapeutics Cancer Vaccines' Phase I Pipeline 71 5.3.10 Therapeutic Cancer Vaccines Market ' Discovery and Pre-Clinical Pipeline 78 5.3.11 Technology Trends Analytic Framework 79

5

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

5.4 Cancer Vaccines Market ' Pipeline by Mechanism of Action 82 5.5 Cancer Vaccines ' Promising Drugs under Clinical Development 83 5.6 Molecule Profile for Promising Drugs Under Clinical Development (Prophylactic Cancer Vaccine) 83 5.6.1 V503 83 5.7 Molecule Profiles of Promising Drugs Under Clinical Development (Therapeutic Cancer Vaccines) 85 5.7.1 Stimuvax 85 5.7.2 OncoVAX 86 5.7.3 Oncovex (GM-CSF) 87 5.7.4 Lucanix (belagenpumatucel-L) 88 5.7.5 Trovax 89 5.7.6 HyperAcute Pancreas 89 5.7.7 Allovectin-7 90 5.7.8 IMA901 91 5.7.9 BiovaxID 91 5.7.10 MAGE-A3 ASCI 92 5.8 Key Takeaway 93 6 Cancer Vaccines - Clinical Trials Mapping 94 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 94 6.2 Clinical Trials by Phase 95 6.3 Clinical Trials by Trial Status 96 6.4 Prominent Sponsors 97 6.5 Top Companies Participating in Cancer Vaccines Clinical Trials 99 7 Cancer Vaccines - Strategic Assessment 100 7.1 Key Events Impacting the Future Market 100 7.2 Cancer Vaccines: Implications for Future Market Competition 101 8 Cancer Vaccines - Future Players 103 8.1 Introduction 103 8.2 Company Profiles 103 8.2.1 Vical Incorporated 103

6

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

8.2.2 Vaccinogen 105 8.2.3 Newlink Genetics Corporation 106 8.2.4 Biovest International (Subsidiary of Accentual Biopharmaceuticals, Inc.) 106 8.2.5 Oxford Biomedica 108 8.2.6 immatics biotechnologies GmbH 110 8.2.7 NovaRx Corporation 110 8.2.8 Oncothyreon 111 8.2.9 Other Companies in the Cancer Vaccines Market 112 9 Cancer Vaccines - Licensing and Partnership Deals 115 10 Cancer Vaccines - Appendix 133 10.1 Market Definitions 133 10.2 Abbreviations 133 10.3 Methodology 135 10.3.1 Coverage 135 10.3.2 Secondary Research 135 10.3.3 Forecasting 136 10.3.4 Primary Research 138 10.3.5 Expert Panel Validation 139 10.4 Contact Us 139 10.5 Disclaimer 139 10.6 Bibliography 140 List of Tables Table1: Cancer Incidence and Mortality in the US, 2010 8 Table 2: Cancer Incidence and Mortality in Europe (EU5), 2010 9 Table 3: Cancer Incidence and Mortality in Japan, 2010 9 Table 4: Difference Between Autologous and Allogenic Tumor Cell Vaccines. 10 Table 5: Cancer Vaccines Market, Global, Revenue ($m), 2006'2010 22 Table 6: Cancer Vaccines Market, Global, Forecast, Revenue ($m), 2010'2018 24 Table 7: Cancer Vaccines Market, The US, Revenue ($m), 2006'2010 25

7

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Table 8: Cancer Vaccines Market, The US, Forecasts, Revenue ($m), 2010'2018 27 Table 9: Cancer Vaccines Market, France, Revenue ($m), 2006'2010 28 Table 10: Cancer Vaccines Market, France, Forecasts, Revenue ($m), 2010'2018 30 Table 11: Cancer Vaccines Market, Germany, Revenue ($m), 2006'2010 31 Table 12: Cancer Vaccines Market, Germany, Forecasts, Revenue ($m), 2010'2018 33 Table 13: Cancer Vaccines Market, Italy, Revenue ($m), 2006'2010 34 Table 14: Cancer Vaccines Market, Italy, Forecasts, Revenue ($m), 2010'2018 36 Table 15: Cancer Vaccines Market, Spain, Revenue ($m), 2006'2010 37 Table 16: Cancer Vaccines Market, Spain, Forecast Revenue ($m), 2010'2018 39 Table 17: Cancer Vaccines Market, The UK, Revenue ($m), 2006'2010 40 Table 18: Cancer Vaccines Market, The UK, Forecasts ($m), 2010'2018 42 Table 19: Cancer Vaccines Market, Japan, Forecasts ($m), 2010'2018 44 Table 20: Gardasil Approvals and Fillings 51 Table 21: Prophylactic Cancer Vaccines' Phase III Pipeline, 2011 57 Table 22: Prophylactic Cancer Vaccines' Phase II Pipeline, 2011 58 Table 23: Prophylactic Cancer Vaccines' Phase I/II Pipeline, 2011 58 Table 24: Prophylactic Cancer Vaccines' Phase II Pipeline, 2011 58 Table 25: Prophylactic Cancer Vaccines'Preclinical Pipeline, 2011 58 Table 26: Therapeutic Cancer Vaccines' Phase III Pipeline, 2011 59 Table 27: Therapeutic Cancer Vaccines ' Phase II Pipeline, 2011 60 Table 28: Therapeutic Cancer Vaccines ' PhaseI/II Pipeline, 2011 66 Table 29: Therapeutic Cancer Vaccines ' Phase I Pipeline, 2011 71 Table 30: Therapeutic Cancer Vaccines ' Discovery and Pre-Clinical Pipeline 2011 78 Table 31: Prophylactic Cancer Vaccines ' Most Promising Drugs Under Clinical Development, 2011 83 Table 32: Therapeutic Cancer Vaccines ' Most Promising Drugs Under Clinical Development, 2011 84 Table 33: Cancer Vaccines ' Clinical Trials by Country, 2011 94 Table 34: Cancer Vaccines - Clinical Trials by Phase, 2011 95 Table 35: Cancer Vaccines - Clinical Trials by Status, 2011 96 Table 36: Cancer Vaccines - Prominent Sponsors, 2011 98

8

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Table 37: Cancer Vaccines - Top Companies Participating in Therapeutics Clinical Trials, 2011 99 Table 38: Vical' Cancer vaccines, Pipeline, 2011 105 Table 39: Vaccinogen- Cancer vaccines Pipeline, 2011 105 Table 40: Newlink Genetics Corporation, Cancer Vaccines Pipeline, 2011 106 Table 41: Biovest International, Cancer vaccines Pipeline, 2011 107 Table 42: Oxford BioMedica, Pipeline, 2011 109 Table 43: immatics biotechnologies , Cancer Vaccines Pipeline, 2011 110 Table 44: NovaRx Corporation,Cancer Vaccines Pipeline, 2011 110 Table 45: Oncothyreon, Cancer Vaccines Pipeline, 2011 111 Table 46: Cancer Vaccines Market ' Future Players 112 Table 47: Cancer Vaccines, Global, Deals 115 List of Figures Figure 1: Mechanism of Action of Tumor Cell Vaccine 11 Figure 2: Immunity Induction Pathway by DNA Vaccines. 13 Figure 3: Manner in which Therapeutic Cancer Vaccines are Given in Clinics 16 Figure 4: Cancer Vaccines Market, Global, Revenue ($m), 2006'2010 21 Figure 5: Prophylactic Cancer Vaccines Market, Global, Forecast ($m), 2010'2018 23 Figure 6: Therapeutic Cancer Vaccines Market, Global, Forecast ($m), 2010'2018 23 Figure 7: Cancer Vaccines Market, The US, Revenue ($m), 2006'2010 25 Figure 8: Prophylactic Cancer Vaccines Market, The US, Forecast ($m), 2010'2018 26 Figure 9: Therapeutic Cancer Vaccines Market, The US, Forecast ($m), 2010'2018 27 Figure 10: Cancer Vaccines Market, France, Revenue ($m), 2006'2010 28 Figure 11: Prophylactic Cancer Vaccines Market, France, Forecast ($m), 2010'2018 29 Figure 12: Therapeutic Cancer Vaccines Market, France, Forecast ($m), 2010'2018 30 Figure 13: Cancer Vaccines Market, Germany, Revenue ($m), 2006'2010 31 Figure 14: Prophylactic Cancer Vaccines Market, Germany, Forecast ($m), 2010'2018 32 Figure 15: Therapeutic Cancer Vaccines Market, Germany, Forecast ($m), 2010'2018 33 Figure 16: Cancer Vaccines Market, Italy, Revenue ($m), 2006'2010 34 Figure 17: Prophylactic Cancer Vaccines Market, Italy, Forecast ($m), 2010'2018 35

9

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Figure 18: Therapeutic Cancer Vaccines Market, Italy, Forecast ($m), 2010'2018 36 Figure 19: Cancer Vaccines Market, Spain, Revenue ($m), 2006'2010 37 Figure 20: Prophylactic Cancer Vaccines Market, Spain, Forecast ($m), 2010'2018 38 Figure 21: Therapeutic Cancer Vaccines Market, Spain, Forecast ($m), 2010'2018 39 Figure 22: Cancer Vaccines Market, The UK, Revenue ($m), 2006'2010 40 Figure 23: Prophylactic Cancer Vaccines Market, The UK, Forecast ($m), 2010'2018 41 Figure 24: Therapeutic Cancer Vaccines Market, The UK, Forecast ($m), 2010'2018 42 Figure 25: Prophylactic Cancer Vaccines Market, Japan, Forecast ($m), 2010'2018 43 Figure 26: Therapeutic Cancer Vaccines Market, Japan, Forecast ($m), 2010'2018 44 Figure 27: Opportunity and Unmet Need in the Prophylactic Cancer Vaccines Market, 2011 47 Figure 28: Opportunity and Unmet Need in the Therapeutic Cancer Vaccines Market, 2011 48 Figure 29: Prophylactic Cancer Vaccines ' Strategic Competitor Assessment, 2011 49 Figure 30: Therapeutic Cancer Vaccines ' Strategic Competitor Assessment, 2011 50 Figure 31: Prophylactic Cancer Vaccines ' Pipeline by Phases of Development, 2011 57 Figure 32: Therapeutic Cancer Vaccines ' Pipeline by Phase of Development, 2011 57 Figure 33: Prophylactic Cancer Vaccines ' Technology Trends Analytics Framework, 2011 79 Figure 34: Prophylactic Cancer Vaccines ' Technology Trends Analytics Framework ' Description, 2011 80 Figure 35: Therapeutic Cancer Vaccines' Technology Trends Analytics Framework ' Description, 2011 81 Figure 36: Prophylactic Cancer Vaccines ' Pipeline by Mechanism of Action, 2011 82 Figure 37: Therapeutic Cancer Vaccines ' Pipeline by Mechanism of Action, 2011 83 Figure 38: Cancer Vaccines ' Clinical Trials by Country, 2011 94 Figure 39: Cancer Vaccines - Clinical Trials by Phase, 2011 95 Figure 40: Cancer Vaccines - Clinical Trials by Status, 2011 96 Figure 41: Cancer Vaccines - Overall Sponsors, 2011 97 Figure 42: Cancer Vaccines - Prominent Sponsors, 2011 98 Figure 43: Cancer Vaccines - Prominent Sponsors, 2011 99 Figure 44: Cancer Vaccines Market, Drivers and Barriers ,2011 100 Figure 45: Implications for Future Market Competition in the Prophylactic Cancer Vaccines Market, 2011 101

10

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Figure 46: Implications for Future Market Competition in the Therapeutic Cancer Vaccines Market, 2011 102 Figure 47: Cancer Vaccines Market ' Pipeline by Company, 2011 103 Figure 48: GlobalData Market Forecasting Model 138 Companies Mentioned Vical Incorporated Vaccinogen Newlink Genetics Corporation Biovest International (Subsidiary of Accentual Biopharmaceuticals, Inc.) Oxford Biomedica immatics biotechnologies GmbH NovaRx Corporation Oncothyreon

Related Documents
Vaccines - Global
This package contains 63 vaccine market analyses from the following countries: Austria, Belgium, Bulgaria, Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Moldova, the Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Ukraine, the United Kingdom, Australia,Canada, Chile, Colombia, Ecuador, ...

Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Cardiovascular Drug Market. The report provides a worldwide strategic overview of the pharmaceutical market, including: ' Sales forecast for major product segments: ethical, OTC, generics.' Sales forecast for major drug categories.' Sales forecasts by geographical ...

11

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Global CNS Drug Market: Strategic Assessments of Leading Suppliers
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Market. The report provides a worldwide strategic overview of the pharmaceutical market, including: ' Sales forecast for major product segments: ethical, OTC, generics.' Sales forecast for major drug categories.' Sales forecasts by geographical region: ...

Global Infectious Disease Drug Market: Strategic Assessments of Leading Suppliers
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Infectious Disease Drug Market. The report provides a worldwide strategic overview of the pharmaceutical market, including: ' Sales forecast for major product segments: ethical, OTC, generics.' Sales forecast for major drug categories.' Sales forecasts by ...

Global Oncology Drug Market: Strategic Assessments of Leading Suppliers
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Oncology Drug Market. The report provides a worldwide strategic overview of the pharmaceutical market, including: ' Sales forecast for major product segments: ethical, OTC, generics.' Sales forecast for major drug categories.' Sales forecasts by geographical ...

Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market
Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines MarketSummaryGBI Research, the leading business intelligence provider, has released its latest research, 'Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market', ...

Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, 'Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and ...

12

Cancer Vaccines - Pipeline Assess ment and Market Forecasts to 2018

Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010SummaryGBI Research, the leading business intelligence provider, has released its latest research, 'Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010', ...

Inflammatory Bowel Diseases: World Drug Market 2011-2021
How will the market for inflammatory bowel disease (IBD) treatments perform from 2011' Our new report shows you potential pharmaceutical revenues to 2021, discussing opportunities and market prospects.Discover potential IBD drug revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.See how drugs such as ...

Global Vaccine Market Forecast to 2013
Vaccine represents one of the most attractive and fast growing sectors, with players' revenue exceeding their expectations. The global vaccine market is primarily divided into adult and pediatric segments, further classified into several other sub-segments. Both the adult and pediatric vaccine sectors have sustained the growth momentum and industry participants have been devising strategies to enlarge ...

13

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->